Sciele to launch six medications in 2008

ATLANTA In addition to Sciele’s announcement last week, reported in Drug Store News, that it will launch its new Sular formulation during the first quarter of 2008, the company also announced plans to launch five other drugs this year:

• two new dosages of fenofibrate for the treatment of mixed dyslipidemia
• Prandin for Type 2 diabetes
• PrandiMet for Type 2 diabetes (pending FDA approval)
• a head lice asphyxiation product (pending FDA approval)
• a women’s health product

Sciele reaffirmed its full-year guidance at the JPMorgan 26th Annual Health Care Conference yesterday. As previously announced, full-year 2007 revenue is expected to range between $375 million and $385 million. The company expects full-year 2008 revenues to range from $440 million to $455 million.